Uli Alf Hacksell
Président chez MEDIVIR AB
Fortune : 313 205 $ au 30/06/2024
Postes actifs de Uli Alf Hacksell
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FLERIE INVEST AB | Directeur/Membre du Conseil | 01/01/2016 | - |
| Independent Dir/Board Member | 01/01/2016 | - | |
| MEDIVIR AB | Président | 05/05/2021 | - |
| Directeur/Membre du Conseil | 15/10/2018 | 05/05/2021 | |
| Directeur Général | 15/10/2018 | 26/05/2020 | |
| President | 15/10/2018 | 26/05/2020 | |
| ACTIVE BIOTECH AB | Directeur/Membre du Conseil | 23/05/2019 | - |
| Independent Dir/Board Member | 23/05/2019 | - | |
| Beactica Therapeutics | Directeur/Membre du Conseil | - | - |
Historique de carrière de Uli Alf Hacksell
Anciens postes connus de Uli Alf Hacksell
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SYNACT PHARMA AB | Directeur/Membre du Conseil | - | 25/05/2023 |
| Président | 25/05/2023 | 20/03/2024 | |
| ADHERA THERAPEUTICS, INC. | Président | 01/07/2018 | 10/07/2020 |
| AVALO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/04/2019 | 18/06/2020 |
| Directeur Général | 01/01/2016 | 14/08/2017 | |
| Président | 01/01/2016 | 15/04/2019 | |
| President | 01/01/2016 | 15/08/2017 | |
Glionova AB
 Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Président | - | 01/01/2017 |
| ACADIA PHARMACEUTICALS INC. | Comptroller/Controller/Auditor | 18/04/2014 | 11/03/2015 |
| Directeur/Membre du Conseil | 12/07/2011 | 11/03/2015 | |
| Directeur Général | 01/09/2000 | 11/03/2015 | |
| President | 01/09/2000 | 11/03/2015 | |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░ ░░ | ░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ | - | - |
Formation de Uli Alf Hacksell
| University of Uppsala | Doctorate Degree |
Statistiques
Internationale
| Suède | 15 |
| Etats-Unis | 4 |
| Danemark | 3 |
Opérationnelle
| Director/Board Member | 9 |
| Chairman | 9 |
| Chief Executive Officer | 4 |
Sectorielle
| Health Technology | 13 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| AVALO THERAPEUTICS, INC. | Health Technology |
| FLERIE INVEST AB | Health Technology |
| MEDIVIR AB | Health Technology |
| ADHERA THERAPEUTICS, INC. | Health Technology |
| ACTIVE BIOTECH AB | Health Technology |
| SYNACT PHARMA AB | Health Technology |
| ANNEXIN PHARMACEUTICALS AB | Health Technology |
| Entreprise privées | 11 |
|---|---|
Action Pharma A/S
 Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Health Technology |
European Federation for Medicinal Chemistry
 European Federation for Medicinal Chemistry Miscellaneous Commercial ServicesCommercial Services The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) is an independent association representing 30 scientific organizations from 26 European countries and over 9000 scientists. The EFMC aims to advance the science of medicinal chemistry and chemical biology by promoting cooperation and networking, providing training and mentoring, rewarding scientific excellence, and facilitating communication and influencing stakeholders. The EFMC² - Computational Chemistry Initiative aims to strengthen the EFMC modeling/digital/informatics community in digital techniques across Europe and connect industry and academia. The Young Scientist Network of the EFMC hosts a mentoring program for PhDs and post-docs seeking a career in medicinal chemistry and chemical biology. | Commercial Services |
Astra AB
 Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Health Technology |
| Astra Arcus AB | |
Glionova AB
Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Health Technology |
InDex Pharmaceuticals AB
 InDex Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden. | Health Technology |
| SynAct Pharma ApS | |
| Astra Draco AB | |
Beactica Therapeutics AB
 Beactica Therapeutics AB Medical DistributorsDistribution Services Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden. | Distribution Services |
| Beactica Therapeutics | |
| Acadia Pharmaceuticals AB |
- Bourse
- Insiders
- Uli Alf Hacksell
- Expérience
